BioSpace News Archive

Element Biosciences Inc., developer of a new and disruptive DNA sequencing platform, is hosting a virtual event to launch its AVITI benchtop sequencer that offers unprecedented performance, cost and flexibility.

Blade Therapeutics, Inc. announced that Wendye Robbins, M.D., president and CEO, will present at two investor conferences in March.

Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA ® (pegloticase injection) Plus Methotrexate for People Living With Uncontrolled Gout.

AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that it will report full year 2021 financial results on Monday, March 14, 2022.

LAVATherapeuticsN.V.(Nasdaq:LVTX), an immuno-oncology company focused on developing its proprietary Gammabody™ platformof bispecific gamma delta T cell engagers (bsTCEs) to transform the treatment of cancer, today announced initial data from its first clinical study with LAVA-051.

Astellas Pharma Inc. today announced topline results from the Phase 3 SKYLIGHT 4™ clinical trial investigating the long-term safety of fezolinetant.

Q BioMed Inc. announced today that it has received a confirmed $500,000 order for Strontium Chloride USP Injections.

GlycoMantra has been granted worldwide, exclusive rights to a UMB technology to advance the company’s pipeline of therapeutics for treating drug-resistant metastatic colorectal cancer.

Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, a majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that the companies will host a business update conference call on Monday, March 28, 2022, at 4:30 PM EDT.

Trinity Life Sciences, a leader in global life sciences commercialization solutions addresses the importance of diversity in clinical trials with support from its Diversity, Equity and Inclusion (DEI) committee in a new white paper entitled Diversity in Clinical Trials Participation: A Life Sciences Perspective.